Skip to main content

The Genetics Company, Discovery Partners to Screen Drug Candidates for Colon Cancer

NEW YORK, Sept. 24 – The Genetics Company and Discovery Partners have partnered to identify potential drug targets for colon cancer, the companies said on Monday.

Discovery Partners, of San Diego, will screen thousands of chemical compounds for their ability to inhibit a protein that The Genetics Company has in previous studies linked to colon cancer.

The agreement calls for The Genetics Company, of Zurich, Switzerland, to hold patent rights to any drug candidates that result from the research. In return, the company will pay Discovery Partners milestone payments and fees, including those for completed experiments and access to the substance libraries.

Further financial details were not disclosed.

The Genetics Company, which is privately held, uses its mouse and fruit fly model systems in functional genomics to help discover new drug targets. In addition to colon cancer, the company hopes to develop therapeutic compounds for endocrine disorders, inflammatory conditions, tissue regeneration, parasites, and other cancers.

In May, Discovery Partners completed its $1.7 million acquisition of Xenometrix , a Colorado-based developer of assays for screening drug candidates.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.